stoxline Quote Chart Rank Option Currency Glossary
  
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
8.2  -0.11 (-1.32%)    06-20 12:13
Open: 8.4
High: 8.4
Volume: 50,019
  
Pre. Close: 8.31
Low: 8.115
Market Cap: 100(M)
Technical analysis
2025-06-20 11:45:46 AM
Short term     
Mid term     
Targets 6-month :  11.04 1-year :  12.89
Resists First :  9.45 Second :  11.04
Pivot price 8.56
Supports First :  7.81 Second :  6.8
MAs MA(5) :  8.47 MA(20) :  8.28
MA(100) :  7.44 MA(250) :  22.04
MACD MACD :  0.3 Signal :  0.4
%K %D K(14,3) :  50.4 D(3) :  57.8
RSI RSI(14): 51.2
52-week High :  61.9 Low :  4.63
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CRBP ] has closed above bottom band by 34.4%. Bollinger Bands are 9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.47 - 8.53 8.53 - 8.57
Low: 7.98 - 8.04 8.04 - 8.1
Close: 8.22 - 8.31 8.31 - 8.39
Company Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Headline News

Tue, 17 Jun 2025
Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data? - Seeking Alpha

Thu, 22 May 2025
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - GlobeNewswire

Thu, 22 May 2025
Corbus Pharmaceuticals CEO Set to Reveal Latest Corporate Strategy at Major Jefferies Healthcare Conference - Stock Titan

Mon, 19 May 2025
Corbus Pharmaceuticals Appoints Industry Leader as Chair with 3 Major Clinical Readouts Coming - Stock Titan

Tue, 06 May 2025
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update - Yahoo Finance

Tue, 06 May 2025
Corbus Pharmaceuticals Receives FDA Fast Track Designation - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 12 (M)
Shares Float 8 (M)
Held by Insiders 0.7 (%)
Held by Institutions 93.2 (%)
Shares Short 1,890 (K)
Shares Short P.Month 2,140 (K)
Stock Financials
EPS -4.24
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.39
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -27.2 %
Return on Equity (ttm) -44.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -3.44
Sales Per Share 0
EBITDA (p.s.) -4.68
Qtrly Earnings Growth 0 %
Operating Cash Flow -50 (M)
Levered Free Cash Flow -34 (M)
Stock Valuations
PE Ratio -1.94
PEG Ratio 0
Price to Book value 0.78
Price to Sales 0
Price to Cash Flow -2
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android